| Rockwell proceeding with Phase III trial of dialysate-added iron. |
|
| Globe Newswire: Rockwell Medical ... announced today that it has commenced enrollment in its pivotal Phase III CRUISE-1 clinical study, designed to treat iron deficiency anemia in hemodialysis dependent-chronic kidney disease patients receiving erythropoietin. |